Aducanumab: The first targeted Alzheimer's therapy

Alzheimer's disease (AD) is an irreversible brain disorder associated with severe progressive dementia and is characterized by deposits of amyloid plaques in the brain. Over the past 20 years, the mortality of strokes and heart disease has decreased, but deaths from AD have increased. The four drugs used clinically to treat AD can only relieve symptoms but cannot slow the progression of the disease. Aducanumab, a human monoclonal antibody that preferentially binds to aggregated amyloid-beta to reduce the number of amyloid plaques and slow disease progression, was approved to treat AD by the US Food and Drug Administration on June 7, 2021. It is the first disease-modifying therapy for AD, but there is considerable controversy regarding the drug's approval. Aducanumab offers hope for millions of patients.

Automated summary

Alzheimer's disease is an irreversible brain disorder characterized by severe progressive dementia. Aducanumab, the first disease-modifying therapy for AD, was approved by the US Food and Drug Administration in June 2021, but its approval has been controversial.